Sarafotoxin S6c
(Synonyms: SRTX-c) 目录号 : GC17987
Sarafotoxin S6c是一种能够特异性激活内皮素B受体的肽类毒素。
Cas No.:121695-87-2
Sample solution is provided at 25 µL, 10mM.
Sarafotoxin S6c is a peptide toxin that specifically activates the endothelin B receptor[1]. Sarafotoxin S6c binds with high affinity to the endothelin B receptor and triggers its downstream signaling pathway, leading to the contraction of vascular smooth muscle; this effect is independent of the integrity of the vascular endothelium[2]. Sarafotoxin S6c is also used to study the role of the endothelin system in cardiovascular physiology and pathological processes, including investigations into disease mechanisms such as pulmonary arterial hypertension[3-4].
In vitro, pretreatment of human hepatic myofibroblastic Ito cells with Sarafotoxin S6c (100nM), followed by stimulation with human serum (2–5%) or platelet-derived growth factor-BB (PDGF-BB; 20ng/ml) for 30 hours, resulted in significant inhibition of DNA synthesis and cell proliferation. This was accompanied by reduced mitogen-activated protein kinase (MAP kinase) activity and decreased c-jun mRNA expression[5].
In vivo, a single intraplantar injection of Sarafotoxin S6c (3–30pmol/paw) in mice 30 minutes prior to administration did not significantly affect capsaicin (0.1μg/paw)-induced nociceptive responses and did not produce a hyperalgesic effect[6].
References:
[1] Bdolah A, Wollberg Z, Fleminger G, et al. SRTX-d, a new native peptide of the endothelin/sarafotoxin family. FEBS Lett. 1989 Oct 9;256(1-2):1-3.
[2] Mills RG, Ralston GB, King GF. The solution structure of sarafotoxin-c. Implications for ligand recognition by endothelin receptors. J Biol Chem. 1994 Sep 23;269(38):23413-9.
[3] Wollberg Z, Bdolah A, Kochva E. Vasoconstrictor effects of sarafotoxins in rabbit aorta: structure-function relationships. Biochem Biophys Res Commun. 1989 Jul 14;162(1):371-6.
[4] Wollberg Z, Bdolah A, Galron R, et al. Contractile effects and binding properties of endothelins/sarafotoxins in the guinea pig ileum. Eur J Pharmacol. 1991 May 30;198(1):31-6.
[5] Mallat A, Fouassier L, Préaux AM, et al. Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway. J Clin Invest. 1995 Jul;96(1):42-9.
[6] Piovezan AP, D'Orléans-Juste P, Tonussi CR, Rae GA. Effects of endothelin-1 on capsaicin-induced nociception in mice. Eur J Pharmacol. 1998 Jun 12;351(1):15-22.
Sarafotoxin S6c是一种能够特异性激活内皮素B受体的肽类毒素[1]。Sarafotoxin S6c可以高效地与内皮素B受体结合并激活其下游信号通路,进而引起血管平滑肌收缩,该作用不依赖于血管内皮的完整性[2]。Sarafotoxin S6c也被用于研究内皮素系统在心血管生理和病理过程中的作用,包括在肺动脉高压等疾病机制探索中的应用[3-4]。
在体外,Sarafotoxin S6c(100nM)预处理人肝肌纤维母细胞性Ito细胞,随后以人血清(2–5%)或血小板衍生生长因子-BB(PDGF-BB;20ng/ml)刺激30小时,Sarafotoxin S6c显著抑制DNA合成及细胞增殖,同时降低丝裂原活化蛋白激酶(MAP kinase)活性和c-jun mRNA表达[5]。
在体内,Sarafotoxin S6c(3-30pmol/paw)单次足底注射处理小鼠30分钟,对辣椒素(0.1μg/爪)诱导的伤害性反应无显著影响,且不产生痛觉过敏效应[6]。
| Cell experiment [1]: | |
Cell lines | Human hepatic myofibroblastic Ito cells |
Preparation Method | Human myofibroblastic Ito cells were obtained from explants of normal liver and cultured in Dulbecco's modified Eagle's medium (DME) containing a mixture of 5% fetal calf serum and 5% pooled human serum. Quiescent cells were achieved by incubation 100μM Sarafotoxin S6c in serum-free Waymouth medium for 3 days. |
Reaction Conditions | 100μM; 30min |
Applications | Sarafotoxin S6c selectively reduced serum-stimulated mRNA expression of the immediate-early gene c-jun. |
| Animal experiment [2]: | |
Animal models | Swiss mice |
Preparation Method | Mice received an intraplantar (i.pl.) injection of Sarafotoxin S6c (3 to 30pmol/paw) into the right hindpaw. Capsaicin (0.1µg/paw) was injected into the same paw 30 minutes later to induce a nociceptive response. The time spent licking the injected paw was recorded over 5 minutes. |
Dosage form | 3 to 30pmol/paw; i.pl. |
Applications | Sarafotoxin S6c, a selective endothelin ETB receptor agonist, failed to significantly modify capsaicin-induced nociception at all tested doses, in contrast to the hyperalgesic effect observed with endothelin-1. |
References: | |
| Cas No. | 121695-87-2 | SDF | |
| 别名 | SRTX-c | ||
| 化学名 | 3,3'-((2Z,5Z,8Z,11E,14Z,17Z,20Z,23Z,26Z,29Z,37Z,40Z,43Z,46Z)-36-((1Z,4Z,7Z,10Z,13Z,16Z)-3-((1H-imidazol-5-yl)methyl)-15-(sec-butyl)-18-carboxy-9-(carboxymethyl)-1,4,7,10,13,16-hexahydroxy-6-(3-hydroxy-3-iminopropyl)-19-(1H-indol-3-yl)-12-isopropyl-2,5,8,1 | ||
| Canonical SMILES | CCC(C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C1CSSCC(N)/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N\C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/2)CCC(O)=O)CCC(O)=O)CC(O)=O)C(O)C)CCSC)CC(O)=O)CC(O)=N)CSSCC2/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C | ||
| 分子式 | C103H147N27O37S5 | 分子量 | 2515.75 |
| 溶解度 | Soluble to 1 mg/ml in Water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 397.5 μL | 1.9875 mL | 3.975 mL |
| 5 mM | 79.5 μL | 397.5 μL | 795 μL |
| 10 mM | 39.7 μL | 198.7 μL | 397.5 μL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















